|
KMID : 0869620100270040392
|
|
Journal of Korean Society of Hospital Pharmacists
2010 Volume.27 No. 4 p.392 ~ p.399
|
|
|
A Comparison between Palonosetron and Ramosetron in Antiemetic Effect in Patients Administered with Carboplatin-containing Anticancer Drugs
|
|
Ko Young-Joo
Lee Yeon-Ji
Hwang Eun-jeong
La Hyen-O
|
|
|
Abstract
|
|
|
About 70 to 80% of patients who undergo chemotherapy experience chemotherapyinduced nausea and vomiting (CINV), which is one of the most common and important adverse events that affect the quality of life. Palonosetron, one of 5-HT3 receptor antagonists (5-HT3RAs), is used to prevent acute and delayed CINV as the only second-generation drug Between June and September 2009, 103 patients were administered with anticancer drugs containing carboplatin. Among them, patients with cervical, ovarian cancer and non-small cell lung cancer who were treated with carboplatin-paclitaxel or carboplatin-docetaxel, became the subjects of this study. This study was retrospectively performed, and the subjects were classified into two groups, the ramosetron group (R-Group; n=32) and the palonosetron group (P-Group; n=18). The two groups were compared to each other in antiemetic effect and cost. Patients who experienced CINV at least once accounted for 29% and 34% in P-Group and R-Group respectively. 50.9% of P-Group and 45.7% of R-Group took the additional antiemetic drugs. In relation to the cost of antiemetic drugs, P-Group costed a tenth part compared to R-Group.
Also, the cost of adding antiemetics above the drugs included in the regimen, P-Group costed 1/3 less compared to R-Group(p=0.004). In conclusion, palonosetron is as effective as the first-gen-eration of 5-HT3 RAs in frequency of emetogenicity. It is expected to be a useful antiemetic in the points of cost-effectiveness and ease of administration. However, this study was conducted on a small number of patients during a short period, thus it was problematic to evaluate the efficacies. A prospective study needs to be performed, excluding other factors that may influence
nausea and vomiting.
|
|
|
KEYWORD
|
|
|
palonosetron, ramosetron, nausea, vomiting, cost-effectiveness
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|